A081801 (Lung Cancer)

What is the Purpose of this Study?

We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.

What is the Condition Being Studied?

Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults 18 and older who:

  • Have lung cancer that has been removed while on Duke Cancer Study A151216
  • Had their surgery between 33-77 days ago
  • Are negative for the genetic markers EGRF and ALK
Age Group

What is Involved?

If you choose to join this study, you will:

  • Be randomly assigned (like a coin flip) to 1 of 3 treatment groups
    • One group will receive only chemotherapy for 3 months
    • Another group will receive chemotherapy for 3 months followed by immunotherapy for up to 1 year
    • A third group will receive chemotherapy and immunotherapy together for 3 months followed by immunotherapy for up to 10 months
  • Get check-ups from your doctor every 3 months for the first 2 years after treatment
  • Get check-ups from your doctor every 6 months for the 3rd, 4th, and 5th years after treatment
  • Get a yearly check-up from your doctor for 5 more years once you hit the 5-year mark after treatment

Altogether, you will continue to see your doctor and study team for 10 years after treatment.

Study Details

Full Title
Alliance A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO
Principal Investigator
George Barth Geller Distinguished Professor for Research in Cancer
Protocol Number
IRB: PRO00106593
NCT: NCT04267848
Phase III
Enrollment Status